SIC
ACTU

SJS Investment Consulting’s Actuate Therapeutics ACTU Stock Holding History

SJS Investment Consulting’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16 Buy
10
+9
+900% +$21 ﹤0.01% 2843
2026
Q1 		$3 Buy
+1
New +$4 ﹤0.01% 2467

Other funds holding ACTU

TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $994M AUM 11.29% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

SJS Investment Consulting's ACTU Position: Q2 2026 in Review

SJS Investment Consulting increased its Actuate Therapeutics (ACTU) stake by 900% in Q2 2026, buying an estimated $21 and bringing the position to 10 shares worth $16. The position accounts for ﹤0.01% of the portfolio, ranked #2843.

SJS Investment Consulting first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • SJS Investment Consulting held 10 shares of Actuate Therapeutics worth $16 as of Q2 2026.
  • SJS Investment Consulting bought 9 Actuate Therapeutics shares in Q2 2026, an estimated $21.
  • Actuate Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2843 holding.
  • SJS Investment Consulting first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.